Thrombosis Therapy: Focus on Antiplatelet AgentsFang Jing1 and Wei Zhang1,2*
- *Corresponding Author:
- Wei Zhang
Shanghai Engineering Research Center of
Molecular Therapy and Pharmaceutical Innovation
North Zhongshan Road, Shanghai, China
Tel: +86 21 32530498
Fax: +86 21 32530498
E-mail: [email protected]
Received date: June 03, 2013; Accepted date: July 10, 2013; Published date: July 15, 2013
Citation: Jing F, Zhang W (2013) Thrombosis Therapy: Focus on Antiplatelet Agents. Int J Genomic Med 1:103. doi: 10.4172/2332-0672.1000103
Copyright: © 2013 Jing F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Platelet adhesion, activation and aggregation to the injured vessel wall are crucially involved in the pathogenesis of thrombus formation. Agents in theory thwarting these phases would have significant clinical value. The current antiplatelet drugs used in daily clinical practice include COX-1 inhibitor aspirin, ADP P2Y12 receptor antagonist clopidogrel, and the GPIIb-IIIa antagonists (abciximab, eptifibatide and tirofiban). However, confined curative ratio along with unforeseen bleeding risk remains a major puzzle of antiplatelet therapy. With advances in understanding of the molecular basis of platelet in thrombosis, newer antiplatelet agents that targets different stage of thrombus formation have been recently developed, mostly including agents targeting platelet adhesion (GPIV, vWF), activation (GPVI, P2Y12, TPα, PAR1, phosphodiesterase, cyclooxygenase), and aggregation (GPIIb/IIIa). In this article, we will review the advantages and limitations of various antiplatelet agents that have been approved by the US Food and Drug Administration (FDA) or under development.